Skip to main content
. 2022 Oct 12;2022:1968829. doi: 10.1155/2022/1968829

Figure 6.

Figure 6

Further exploration of MAS1L, TCP10L2, and CRHR2. Notes: (a–c) the expression level of MAS1L, TCP10L2, and CRHR2 in normal and tumor tissue; (d–f) disease-specific survival of MAS1L, TCP10L2, and CRHR2; (g–i) progression-free survival of MAS1L, TCP10L2, and CRHR2.